In the latest issue! Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis dlvr.it/TCwQFz

Highly efficient #CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation. Nat Commun 2024-09-16. doi.org/10.1038/s41467… RNP delivery via “droplet cell pincher (DCP)” outperforms electroporations: KO (~6.5-fold), double KO (~3.8-fold) & KI (~3.8-fold)

Scientists have made major strides in engineering #CARTcell therapies to treat #autoimmune disorders such as lupus, according to a new Review that discusses the latest breakthroughs and clinical trials in the field. Dr. Christopher M. Jewell Cartesian Therapeutics bit.ly/3YsPiFy

Today we report in Nature Biotechnology a system for the laboratory evolution of engineered virus-like particles (eVLPs) that enables the discovery of eVLP variants with desired properties, including improved production and delivery potency. 1/13 PDF: drive.google.com/file/d/1E6Nr86…

Announcement: For your calendars the #𝗠𝗶𝗰𝗿𝗼𝗧𝗔𝗦𝟮𝟬𝟮𝟱 𝗔𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘁𝗵𝗲 𝟮𝟬𝘁𝗵 𝗼𝗳 𝗠𝗮𝘆 𝟮𝟬𝟮𝟱! We hope to see all our #microfluidic and #microsystems community in Adelaide, Australia so have your abstracts with us by then!

"... individuals without a hit paper as a postdoc are significantly less likely to pursue a faculty career than those with at least one... " Interesting #publication in PNASNews #Sciencetwitter #phdlife #postdoclife #Science #academia pnas.org/doi/10.1073/pn…

Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy. | Jaiwoo Lee, Korea Univ. | CRS Korea Chapter Jaiwoo Lee Junho Byun [50 days' free access] #HybridNanoparticle #DendriticCell #AntigenPriming kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Our spatial multi-omics technology that co-profiles five modalities is now published in Nature Methods Nature Methods! Huge thanks to Marek Bartosovic, Mingyao Li, and my amazing team, including postdoc Pengfei_Guo and PhD student Liran Mao! nature.com/articles/s4159…

Welcome to the department!!

Promising news for patients who need access to #CRISPR gene therapies. This month, Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for its CRISPR/Cas9 gene editing therapy to treat patients with severe sickle cell disease. investors.vrtx.com/news-releases/…

Thanks for visiting and your amazing talk, Hiro! Hirofumi Shintaku

Big thanks to Prof. Hyun-Gyu Park from CBE KAIST for the visit and amazing talk! 🙏👏

For the first time, researchers have used the #CRISPR gene editor to repair a flawed gene in the human body. scim.ag/4kF7dTI News from Science

Cell and gene therapies are leading the way in clinical success! According to updated research from NEWDIGS, these therapies are 2.5 times more likely to receive FDA approval after entering Phase I trials compared to the average drug. nature.com/articles/d4157…

Check out our recent review paper - Lipid nanoparticles: Composition, formulation, and application - published in Molecular Therapy: Methods & Clinical Development. Congrats to my graduate students Sijia, Fenglin and Zhenzhen. 👉doi.org/10.1016/j.omtm…

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

Today in Science Magazine we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells, a collaboration with Sternberg Lab. 1/13 drive.google.com/file/d/1I-UbCR…

This week's genome editing triumph is a big deal. Here's why erictopol.substack.com/p/the-first-hu…

The CRISPR family’s most versatile member has made its medical debut: a cutting-edge gene-editing technique known as prime editing has been used to treat a person for the first time go.nature.com/4kqr3RK